I. Bello-Rivero

发表

Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: A randomized, double-blind, placebo-controlled study

L. González-Méndez, P. López-Saura, C. Valenzuela-Silva, 2008, BMC infectious diseases.

Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial

E. García‐Iglesias, I. García-García, I. Bello-Rivero, 2012, BMC Pharmacology and Toxicology.

Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2010, BMC pharmacology.

Immunoglobulin E-Dependent Regulation of the CCR3 Chemokine Receptor by Interferon-Gamma in Atopic Asthmatics

P. López-Saura, C. Valenzuela-Silva, I. Bello-Rivero, 2008, International Archives of Allergy and Immunology.

The amino‐terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: internalization is toxin mediated

M. Fabbrini, D. Carpani, M. Soria, 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2005, Biopharmaceutics & drug disposition.

Proteomics and Phospho-Proteomics Profiling of the Co-Formulation of Type I and II Interferons, HeberFERON, in the Glioblastoma-Derived Cell Line U-87 MG

J. Wiśniewski, Osmany Guirola, V. Besada, 2022, bioRxiv.

HeberFERON distinctively targets Cell Cycle in the glioblastoma-derived cell line U-87MG

Jamilet Miranda, R. Bringas, J. Fernández-de-Cossio, 2022, bioRxiv.

Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.

P. López-Saura, I. García, Jesús Pérez, 2004, Journal of autoimmunity.

Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study

P. López-Saura, I. Bello-Rivero, Y. García-Vega, 2009, BMC Cancer.

Five years follow-up of patients with non-melanoma skin cancer treated with HeberFERON

C. Valenzuela-Silva, M. rodríguez-garCía, E. García‐Iglesias, 2022, medRxiv.

Treatment of Basal Cell Carcinoma with Interferons Alpha-2b and Gamma in Primary Care

I. Bello-Rivero, Y. Duncan-Roberts, M. Fernández-Martori, 2018 .

HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment.

Vladimir Besada-Pérez, I. Bello-Rivero, Y. García-Vega, 2018, Seminars in oncology.

Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.

P. López-Saura, J. Cabrera-Gomez, C. Valenzuela-Silva, 2008, International immunopharmacology.

Basal cell carcinoma treated with HeberFERON. A real world retrospective study

O. Reyes-Acosta, I. Bello-Rivero, Y. García-Vega, 2021, medRxiv.

Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2016, BMC Pharmacology and Toxicology.

A combination treatment of IFN-α2b and IFN-γ accelerates viral clearance and control inflammatory response in COVID-19: Preliminary results of a randomized controlled trial

E. Fish, M. Béquet-Romero, F. Hernández-Bernal, 2021 .

Administration of HeberFERON in Patients with Persistent Oropharyngeal SARS-CoV-2 Wuhan/D614G Strain Viral Shedding

M. García-Sánchez, I. Bello-Rivero, Y. Duncan-Roberts, 2021, Journal of Biomedical Research & Environmental Sciences.

Construction, purification, and characterization of a chimeric TH1 antagonist

P. López-Saura, G. Pentón-Rol, Haydee Gerónimo-Pérez, 2006, BMC biotechnology.

Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers

P. López-Saura, C. A. González-Delgado, C. Valenzuela-Silva, 2016, BMC Pharmacology and Toxicology.

Development of a new formulation of interferons (HEBERPAG) for BCC treatment

P. López-Saura, C. Valenzuela-Silva, I. Bello-Rivero, 2013 .

A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status

S. Leenstra, A. Villarreal, I. Bello-Rivero, 2020, Molecular Biology Reports.

A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG

Jamilet Miranda, R. Bringas, J. Fernández-de-Cossio, 2023, BMC Cancer.

BioHabana 2022: Preventive and Immunotherapeutic Strategies Against COVID-19 and Cancer in Cuba.

F. Hernández-Bernal, Y. Morera-Díaz, I. Bello-Rivero, 2023, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

E. García‐Iglesias, I. García-García, I. Bello-Rivero, 2012, BMC Pharmacology and Toxicology.